Targeting the tumor microenvironment: Focus on angiogenesis

Journal of Oncology

Volumn , Issue , 2012, Pages

  Podar, Klaus ^a   Fan, Fengjuan ^a   Schimming, Alexander ^a   Jaeger, Dirk ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; EVEROLIMUS; ICRUCUMAB; IMC 1121 B; IMC 18 F; LAPATINIB; LENALIDOMIDE; PANITUMUMAB; PAZOPANIB; POMALIDOMIDE; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TAMOXIFEN CITRATE; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VATALANIB;

ANGIOGENESIS; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; GENETICS; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; REVIEW; STOMACH CANCER; THYROID CANCER; TUMOR MICROENVIRONMENT; URINARY TRACT CARCINOMA;

EID: 80053483270     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/281261     Document Type: Review

References (208)

1. Stratton M. R., Exploring the genomes of cancer cells: progress and promise Science 2011 331 6024 1553 1558
2. Hahn W. C., Weinberg R. A., Rules for making human tumor cells The New England Journal of Medicine 2002 347 20 1593 1603 (Pubitemid 35315841)
3. Green J. E., Hudson T., The promise of genetically engineered mice for cancer prevention studies Nature Reviews Cancer 2005 5 3 184 198 (Pubitemid 40314950)
4. Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M. M., Bos J. L., Genetic alterations during colorectal-tumor development The New England Journal of Medicine 1988 319 9 525 532
5. Perry A. S., Watson R. W. G., Lawler M., Hollywood D., The epigenome as a therapeutic target in prostate cancer Nature Reviews Urology 2010 7 12 668 680
6. Portela A., Esteller M., Epigenetic modifications and human disease Nature Biotechnology 2010 28 10 1057 1068
7. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation Cell 2011 144 5 646 674
8. Bissell M. J., Hines W. C., Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression Nature Medicine 2011 17 3 320 329
9. Ronnov-Jessen L., Petersen O. W., Bissell M. J., Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction Physiological Reviews 1996 76 1 69 125 (Pubitemid 26048279)
10. Vargo-Gogola T., Rosen J. M., Modelling breast cancer: one size does not fit all Nature Reviews Cancer 2007 7 9 659 672 (Pubitemid 47327411)
11. Banerjee S., Dowsett M., Ashworth A., Martin L. A., Mechanisms of disease: angiogenesis and the management of breast cancer Nature Clinical Practice Oncology 2007 4 9 536 550 (Pubitemid 47351464)
12. Podar K., Chauhan D., Anderson K. C., Bone marrow microenvironment and the identification of new targets for myeloma therapy Leukemia 2009 23 1 10 24
13. Virchow R., Die Krankhaften Geschwlste 1863 Berlin, Germany Hirschwald
14. Goldmann E., The growth of malignant disease in man and the lower animals, with special reference to the vascular system Proceedings of the Royal Society of Medicine 1908 1 1 13
15. Murphy J. B., Transplantability of tissues to the embryo of foreign species: its bearing on questions of tissue specificity and tumor immunity Journal of Experimental Medicine 1913 17 4 482 493
16. Hertig A. T., Angiogenesis in the early human chorion and in the primary placenta of the macaque monkey Contributions to Embryology 1935 25 37 81
17. Ide A. G., Baker N. H., Warren S. L., Vascularization of the Brown Pearce rabbit epithelioma tranplant as seen in the transparent ear chamber American Journal of Roentgenology 1939 42 891 899
18. Folkman J., Tumor angiogenesis: therapeutic implications The New England Journal of Medicine 1971 285 21 1182 1186
19. Ferrara N., Henzel W. J., Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells Biochemical and Biophysical Research Communications 1989 161 2 851 858 (Pubitemid 19162712)
20. Ferrara N., Vascular endothelial growth factor Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 6 789 791
21. Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Susan Harvey V., Dvorak H. F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 1983 219 4587 983 985
22. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N., Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989 246 4935 1306 1309 (Pubitemid 20066716)
23. Keck P. J., Hauser S. D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D. T., Vascular permeability factor, an endothelial cell mitogen related to PDGF Science 1989 246 4935 1309 1312 (Pubitemid 20066717)
24. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364 (Pubitemid 26272076)
25. Ellis L. M., Hicklin D. J., VEGF-targeted therapy: mechanisms of anti-tumour activity Nature Reviews Cancer 2008 8 8 579 591
26. Hanahan D., Weinberg R. A., The hallmarks of cancer Cell 2000 100 1 57 70 (Pubitemid 30046295)
27. Mueller M. M., Fusenig N. E., Friends or foesbipolar effects of the tumour stroma in cancer Nature Reviews Cancer 2004 4 11 839 849 (Pubitemid 39472951)
28. Gordon M. S., Mendelson D. S., Kato G., Tumor angiogeiiesis and novel antiangiogenic strategies International Journal of Cancer 2010 126 8 1777 1787
29. Chung A. S., Lee J., Ferrara N., Targeting the tumour vasculature: insights from physiological angiogenesis Nature Reviews Cancer 2010 10 7 505 514
30. Eilken H. M., Adams R. H., Dynamics of endothelial cell behavior in sprouting angiogenesis Current Opinion in Cell Biology 2010 22 5 617 625
31. Nelson A. R., Fingleton B., Rothenberg M. L., Matrisian L. M., Matrix metalloproteinases: biologic activity and clinical implications Journal of Clinical Oncology 2000 18 5 1135 1149 (Pubitemid 30123793)
32. Nangia-Makker P., Honjo Y., Sarvis R., Akahani S., Hogan V., Pienta K. J., Raz A., Galectin-3 induces endothelial cell morphogenesis and angiogenesis American Journal of Pathology 2000 156 3 899 909 (Pubitemid 30626949)
33. Gamble J., Meyer G., Noack L., Furze J., Matthias L., Kovach N., Harlan J., Vadas M., B1 integrin activation inhibits in vitro tube formation: effects on cell migration, vacuole coalescence and lumen formation Endothelium 1999 7 1 23 34 (Pubitemid 29481521)
34. Yang S., Graham J., Kahn J. W., Schwartz E. A., Gerritsen M. E., Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels American Journal of Pathology 1999 155 3 887 895 (Pubitemid 29426835)
35. Parker L. H., Schmidt M., Jin S. W., Gray A. M., Beis D., Pham T., Frantz G., Palmieri S., Hillan K., Stainier D. Y. R., De Sauvage F. J., Ye W., The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation Nature 2004 428 6984 754 758 (Pubitemid 38514720)
36. Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J., Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 1999 284 5422 1994 1998 (Pubitemid 29309448)
37. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B., Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Reviews Cancer 2002 2 11 826 835 (Pubitemid 37328901)
38. Folberg R., Hendrix M. J. C., Maniotis A. J., Vasculogenic mimicry and tumor angiogenesis American Journal of Pathology 2000 156 2 361 381 (Pubitemid 30648785)
39. Chang Y. S., Di Tomaso E., M D. M., Jones R., Jain R. K., Munn L. L., Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood Proceedings of the National Academy of Sciences of the United States of America 2000 97 26 14608 14613 (Pubitemid 32016623)
40. Yancopoulos G. D., Davis S., Gale N. W., Rudge J. S., Wiegand S. J., Holash J., Vascular-specific growth factors and blood vessel formation Nature 2000 407 6801 242 248
41. Hendrix M. J. C., Seftor E. A., Meltzer P. S., Gardner L. M. G., Hess A. R., Kirschmann D. A., Schatteman G. C., Seftor R. E. B., Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry Proceedings of the National Academy of Sciences of the United States of America 2001 98 14 8018 8023 (Pubitemid 32642679)
42. Folkman J., Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proceedings of the National Academy of Sciences of the United States of America 2001 98 2 398 400 (Pubitemid 32105051)
43. Bergers G., Benjamin L. E., Tumorigenesis and the angiogenic switch Nature Reviews Cancer 2003 3 6 401 410 (Pubitemid 37328844)
44. Iliopoulos O., Levy A. P., Jiang C., Kaelin W. G., Goldberg M. A., Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proceedings of the National Academy of Sciences of the United States of America 1996 93 20 10595 10599 (Pubitemid 26333032)
45. Wiesener M. S., Mnchenhagen P. M., Berger I., Morgan N. V., Roigas J., Schwiertz A., Jrgensen J. S., Gruber G., Maxwell P. H., Lning S. A., Frei U., Maher E. R., Grne H. J., Eckardt K. U., Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1 in clear cell renal carcinomas Cancer Research 2001 61 13 5215 5222 (Pubitemid 32681556)
46. Baldewijns M. M., Van Vlodrop I. J. H., Vermeulen P. B., Soetekouw P. M. M. B., Van Engeland M., De Brune A. P., VHL and HIF signalling in renal cell carcinogenesis Journal of Pathology 2010 221 2 125 138
47. Wacker I., Sachs M., Knaup K., Wiesener M., Weiske J., Huber O., Aketin Z., Behrens J., Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor Molecular and Cellular Biology 2009 29 7 1707 1718
48. Pouysségur J., Dayan F., Mazure N. M., Hypoxia signalling in cancer and approaches to enforce tumour regression Nature 2006 441 7092 437 443 (Pubitemid 44050138)
49. Ghosh G., Subramanian I. V., Adhikari N., Zhang X., Joshi H. P., Basi D., Chandrashekhar Y. S., Hall J. L., Roy S., Zeng Y., Ramakrishnan S., Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF- isoforms and promotes angiogenesis Journal of Clinical Investigation 2010 120 11 4141 4154
50. Loscalzo J., The cellular response to hypoxia: tuning the system with microRNAs Journal of Clinical Investigation 2010 120 11 3815 3817
51. Semenza G. L., Targeting HIF-1 for cancer therapy Nature Reviews Cancer 2003 3 10 721 732 (Pubitemid 37328811)
52. Podar K., Anderson K. C., A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways Cell Cycle 2010 9 9 1722 1728
53. Fearon E. R., Vogelstein B., A genetic model for colorectal tumorigenesis Cell 1990 61 5 759 767
54. Moran A., Ortega P, de Juan C., Differential colorectal carcinogenesis: molecular basis and clinical relevance World Journal of Gastrointestinal Oncology 2010 2 3 151 158
55. Wang D., Huang H. J. S., Kazlauskas A., Cavenee W. K., Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase Cancer Research 1999 59 7 1464 1472 (Pubitemid 29160112)
56. Tortora G., Caputo R., Damiano V., Bianco R., Fontanini G., Cuccato S., De Placido S., Bianco A. R., Ciardiello F., Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis Clinical Cancer Research 2001 7 8 2537 2544 (Pubitemid 32751660)
57. Viloria Petit A. M., Rak J., Hung M. C., Rockwell P., Goldstein N., Fendly B., Kerbel R. S., Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors American Journal of Pathology 1997 151 6 1523 1530 (Pubitemid 27527914)
58. Chin K. F., Greenman J., Gardiner E., Kumar H., Topping K., Monson J., Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer British Journal of Cancer 2000 83 11 1425 1431
59. Hyodo I., Doi T., Endo H., Hosokawa Y., Nishikawa Y., Tanimizu M., Jinno K., Kotani Y., Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer European Journal of Cancer 1998 34 13 2041 2045 (Pubitemid 28546939)
60. Nanashima A., Ito M., Sekine I., Naito S., Yamaguchi H., Nakagoe T., Ayabe H., Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers Digestive Diseases and Sciences 1998 43 12 2634 2640 (Pubitemid 29034916)
61. Taketo M. M., Cyclooxygenase-2 inhibitors in tumorigenesis (part II) Journal of the National Cancer Institute 1998 90 21 1609 1620 (Pubitemid 28523435)
62. Milas L., Kishi K., Hunter N., Mason K., Masferrer J. L., Tofilon P. J., Enhancement of tumor response to -radiation by an inhibitor of cyclooxygenase-2 enzyme Journal of the National Cancer Institute 1999 91 17 1501 1504 (Pubitemid 29424556)
63. Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., Dubois R. N., Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 1994 107 4 1183 1188 (Pubitemid 24294584)
64. Gupta R. A., DuBois R. N., Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 Nature Reviews Cancer 2001 1 1 11 21 (Pubitemid 33741877)
65. Ogino S., Kirkner G. J., Nosho K., Irahara N., Kure S., Shima K., Hazra A., Chan A. T., Dehari R., Giovannucci E. L., Fuchs C. S., Cyclooxygenase-2 expression Is an independent predictor of poor prognosis in colon cancer Clinical Cancer Research 2008 14 24 8221 8227
66. Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M., Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 1996 87 5 803 809 (Pubitemid 26404280)
67. Shattuck-Brandt R. L., Lamps L. W., Heppner Goss K. J., DuBois R. N., Matrisian L. M., Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms Molecular Carcinogenesis 1999 24 3 177 187 (Pubitemid 29169858)
68. Hong B. K., Kwon H. M., Lee B. K., Kim D., Kim I. J., Kang S. M., Jang Y., Cho S. H., Kim H. K., Jang B. C., Cho S. Y., Kim H. S., Kim M. S., Kwon H. C., Lee N., Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions Yonsei Medical Journal 2000 41 1 82 88
69. Dempke W., Rie C., Grothey A., Schmoll H. J., Cyclooxygenase-2: a novel target for cancer chemotherapy? Journal of Cancer Research and Clinical Oncology 2001 127 7 411 417 (Pubitemid 32524357)
70. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R. N., Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 1998 93 5 705 716 (Pubitemid 28257578)
71. Majima M., Isono M., Ikeda Y., Hayashi I., Hatanaka K., Harada Y., Katsumata O., Yamashina S., Katori M., Yamamoto S., Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants Japanese Journal of Pharmacology 1997 75 2 105 114 (Pubitemid 27491544)
72. Masferrer J. L., Leahy K. M., Koki A. T., Zweifel B. S., Settle S. L., Woerner B. M., Edwards D. A., Flickinger A. G., Moore R. J., Seibert K., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Research 2000 60 5 1306 1311 (Pubitemid 30151999)
73. Uefuji K., Ichikura T., Mochizuki H., Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer Clinical Cancer Research 2000 6 1 135 138 (Pubitemid 30064985)
74. DuBois R. N., Smalley W. E., Cyclooxygenase, NSAIDs, and colorectal cancer Journal of Gastroenterology 1996 31 6 898 906 (Pubitemid 27042276)
75. Ruder E. H., Laiyemo A. O., Graubard B. I., Hollenbeck A. R., Schatzkin A., Cross A. J., Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort American Journal of Gastroenterology 2011 106 7 1340 1350
76. Arthur H. M., Ure J., Smith A. J. H., Renforth G., Wilson D. I., Torsney E., Charlton R., Parums D. V., Jowett T., Marchuk D. A., Burn J., Diamond A. G., Endoglin, an ancillary TGF receptor, is required for extraembryonic angiogenesis and plays a key role in heart development Developmental Biology 2000 217 1 42 53 (Pubitemid 30046798)
77. Li C., Guo B., Bernabeu C., Kumar S., Angiogenesis in breast cancer: the role of transforming growth factor and CD105 Microscopy Research and Technique 2001 52 4 437 449 (Pubitemid 32167832)
78. Romani A. A., Borghetti A. F., Del Rio P., Sianesi M., Soliani P., The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count Journal of Surgical Oncology 2006 93 6 446 455 (Pubitemid 44651267)
79. Venkatesha S., Toporsian M., Lam C., Hanai J. I., Mammoto T., Kim Y. M., Bdolah Y., Lim K. H., Yuan H. T., Libermann T. A., Stillman I. E., Roberts D., D'Amore P. A., Epstein F. H., Sellke F. W., Romero R., Sukhatme V. P., Letarte M., Karumanchi S. A., Soluble endoglin contributes to the pathogenesis of preeclampsia Nature Medicine 2006 12 6 642 649 (Pubitemid 43865232)
80. Walshe T. E., Saint-Geniez M., Maharaj A. S. R., Sekiyama E., Maldonado A. E., D'Amore P. A., TGF- is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature PLoS One 2009 4 4
81. Rini B. I., Campbell S. C., Escudier B., Renal cell carcinoma The Lancet 2009 373 9669 1119 1132
82. Lam J. S., Leppert J. T., Belldegrun A. S., Figlin R. A., Novel approaches in the therapy of metastatic renal cell carcinoma World Journal of Urology 2005 23 3 202 212 (Pubitemid 41136043)
83. Sun M., Lughezzani G., Perrotte P., Karakiewicz P. I., Treatment of metastatic renal cell carcinoma Nature Reviews Urology 2010 7 6 327 338
84. Takahashi A., Sasaki H., Kim S. J., Tobisu K. I., Kakizoe T., Tsukamoto T., Kumamoto Y., Sugimura T., Terada M., Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis Cancer Research 1994 54 15 4233 4237 (Pubitemid 24258135)
85. Cohen H. T., McGovern F. J., Renal-cell carcinoma The New England Journal of Medicine 2005 353 23 2477 2490 (Pubitemid 41770167)
86. Iliopoulos O., Kibel A., Gray S., Kaelin W. G., Tumour suppression by the human von Hippel-Lindau gene product Nature Medicine 1995 1 8 822 826
87. Chen F., Kishida T., Duh F. M., Renbaum P., Orcutt M. L., Schmidt L., Zbar B., Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene Cancer Research 1995 55 21 4804 4807
88. Zimmer M., Doucette D., Siddiqui N., Iliopoulos O., Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors Molecular Cancer Research 2004 2 2 89 95 (Pubitemid 38250425)
89. Gossage L., Eisen T., Alterations in VHL as potential biomarkers in renal-cell carcinoma Nature Reviews Clinical Oncology 2010 7 5 277 288
90. Ohh M., Yauch R. L., Lonergan K. M., Whaley J. M., Stemmer-Rachamimov A. O., Louis D. N., Gavin B. J., Kley N., Kaelin W. G., Iliopoulos O., The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Molecular Cell 1998 1 7 959 968 (Pubitemid 128379257)
91. Kurban G., Duplan E., Ramlal N., Hudon V., Sado Y., Ninomiya Y., Pause A., Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2 Oncogene 2008 27 7 1004 1012 (Pubitemid 351225387)
92. Carroll V. A., Ashcroft M., Regulation of angiogenic factors by HDM2 in renal cell carcinoma Cancer Research 2008 68 2 545 552 (Pubitemid 351380083)
93. Thompson R. H., Kuntz S. M., Leibovich B. C., Dong H., Lohse C. M., Webster W. S., Sengupta S., Frank I., Parker A. S., Zincke H., Blute M. L., Sebo T. J., Cheville J. C., Kwon E. D., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Research 2006 66 7 3381 3385
94. Johnson B. F., Clay T. M., Hobeika A. C., Lyerly H. K., Morse M. A., Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy Expert Opinion on Biological Therapy 2007 7 4 449 460 (Pubitemid 46524672)
95. Biswas S., Eisen T., Immunotherapeutic strategies in kidney cancerwhen TKIs are not enough Nature Reviews Clinical Oncology 2009 6 8 478 487
96. American Cancer Society, Cancer Facts Figures 2010 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf
97. Harris A. L., Fox S., Bicknell R., Leek R., Relf M., LeJeune S., Kaklamanis L., Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer Cancer 1994 74 3 1021 1025 (Pubitemid 24231997)
98. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Viloria-Petit A., Filmus J., Mansour S. J., Ahn N. G., Kerbel R. S., Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts Cancer Research 2000 60 2 490 498 (Pubitemid 30070780)
99. Brown L. F., Guidi A. J., Schnitt S. J., Van De Water L., Iruela-Arispe M. L., Yeo T. K., Tognazzi K., Dvorak H. F., Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast Clinical Cancer Research 1999 5 5 1041 1056 (Pubitemid 29233218)
100. Kimbro K. S., Simons J. W., Hypoxia-inducible factor-1 in human breast and prostate cancer Endocrine-Related Cancer 2006 13 3 739 749 (Pubitemid 44763255)
101. Scorilas A., Karameris A., Arnogiannaki N., Ardavanis A., Bassilopoulos P., Trangas T., Talieri M., Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients British Journal of Cancer 2001 84 11 1488 1496 (Pubitemid 32579341)
102. Bergers G., Brekken R., McMahon G., Vu T. H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D., Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nature Cell Biology 2000 2 10 737 744
103. Greb R. R., Maier I., Wallwiener D., Kiesel L., Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions British Journal of Cancer 1999 81 2 225 231 (Pubitemid 29423699)
104. Mueller M. D., Vigne J. L., Minchenko A., Lebovic D. I., Leitman D. C., Taylor R. N., Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors and Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10972 10977
105. Buteau-Lozano H., Ancelin M., Lardeux B., Milanini J., Perrot-Applanat M., Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors and Cancer Research 2002 62 17 4977 4984 (Pubitemid 34984422)
106. Slamon D. J., Clark G. M., Wong S. G., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987 235 4785 177 182 (Pubitemid 17231334)
107. Piccart-Gebhart M. J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C. H., Steger G., Huang C. S., Andersson M., Inbar M., Lichinitser M., Lng I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T. M., Rschoff J., Sto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M. S., Gelber R. D., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer The New England Journal of Medicine 2005 353 16 1659 1672 (Pubitemid 41464705)
108. Wen X. F., Yang G., Mao W., Thornton A., Liu J., Bast R. C., Le X. F., HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy Oncogene 2006 25 52 6986 6996 (Pubitemid 44684839)
109. Klos K. S., Wyszomierski S. L., Sun M., Tan M., Zhou X., Li P., Yang W., Yin G., Hittelman W. N., Yu D., ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells Cancer Research 2006 66 4 2028 2037
110. Reid P. E., Brown N. J., Holen I., Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact Molecular Cancer 2009 8 49
111. Cross S. S., Yang Z., Brown N. J., Balasubramanian S. P., Evans C. A., Woodward J. K., Neville-Webbe H. L., Lippitt J. M., Reed M. W. R., Coleman R. E., Holen I., Osteoprotegerin (OPG)a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? International Journal of Cancer 2006 118 8 1901 1908
112. Hayashida T., Takahashi F., Chiba N., Brachtel E., Takahashi M., Godin-Heymann N., Gross K. W., Vivanco M. D. M., Wijendran V., Shioda T., Sgroi D., Donahoe P. K., Maheswaran S., HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis Proceedings of the National Academy of Sciences of the United States of America 2010 107 3 1100 1105
113. Greer P., Closing in on the biological functions of Fps/Fes and Fer Nature Reviews Molecular Cell Biology 2002 3 4 278 289 (Pubitemid 34619263)
114. Zhang S., Chitu V., Stanley E. R., Elliott B. E., Greer P. A., Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages Cancer Research 2011 71 4 1465 1473
115. Garvin S., Dabrosin C., Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo Cancer Research 2003 63 24 8742 8748 (Pubitemid 38064052)
116. Nilsson U. W., Jnsson J. A., Dabrosin C., Tamoxifen decreases extracellular TGF- 1 secreted from breast cancer cellsa post-translational regulation involving matrix metalloproteinase activity Experimental Cell Research 2009 315 1 1 9
117. Lindahl G., Saarinen N., Abrahamsson A., Dabrosin C., Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer Cancer Research 2011 71 1 51 60
118. Sirohi B., Powles R., Multiple myeloma The Lancet 2004 363 9412 875 887 (Pubitemid 38368839)
119. Raab M. S., Podar K., Breitkreutz I., Richardson P. G., Anderson K. C., Multiple myeloma The Lancet 2009 374 9686 324 339
120. Ribatti D., Vacca A., The role of microenvironment in tumor angiogenesis Genes and Nutrition 2008 3 1 29 34
121. Vacca A., Ribatti D., Bone marrow angiogenesis in multiple myeloma Leukemia 2006 20 2 193 199 (Pubitemid 43148652)
122. Ribatti D., Nico B., Vacca A., Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma Oncogene 2006 25 31 4257 4266 (Pubitemid 44100496)
123. Podar K., Anderson K. C., The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood 2005 105 4 1383 1395 (Pubitemid 40223651)
124. Hideshima T., Mitsiades C., Tonon G., Richardson P. G., Anderson K. C., Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets Nature Reviews Cancer 2007 7 8 585 598 (Pubitemid 47106630)
125. Podar K., Hideshima T., Chauhan D., Anderson K. C., Targeting signalling pathways for the treatment of multiple myeloma Expert Opinion on Therapeutic Targets 2005 9 2 359 381 (Pubitemid 40613874)
126. Jakob C., Sterz J., Zavrski I., Heider U., Kleeberg L., Fleissner C., Kaiser M., Sezer O., Angiogenesis in multiple myeloma European Journal of Cancer 2006 42 11 1581 1590 (Pubitemid 44118769)
127. Podar K., Anderson K. C., Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies Cell Cycle 2007 6 5 538 542 (Pubitemid 46440425)
128. Vacca A., Ria R., Semeraro F., Merchionne F., Coluccia M., Boccarelli A., Scavelli C., Nico B., Gernone A., Battelli F., Tabilio A., Guidolin D., Petrucci M. T., Ribatti D., Dammacco F., Endothelial cells in the bone marrow of patients with multiple myeloma Blood 2003 102 9 3340 3348 (Pubitemid 37314776)
129. Pellegrino A., Antonaci F., Russo F., Merchionne F., Ribatti D., Vacca A., Dammacco F., CXCR3-binding chemokines in multiple myeloma Cancer Letters 2004 207 2 221 227 (Pubitemid 38457044)
130. Heissig B., Ohki Y., Sato Y., Rafii S., Werb Z., Hattori K., A role for niches in hematopoietic cell development Hematology 2005 10 3 247 253 (Pubitemid 41801141)
131. Kopp H. G., Avecilla S. T., Hooper A. T., Rafii S., The bone marrow vascular niche: home of HSC differentiation and mobilization Physiology 2005 20 5 349 356 (Pubitemid 41457400)
132. Folkman J., Angiogenesis: an organizing principle for drug discovery? Nature Reviews Drug Discovery 2007 6 4 273 286 (Pubitemid 46505878)
133. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085 (Pubitemid 24139577)
134. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeldis J., Barlogie B., Siegel D., Crowley J., Antitumor activity of thalidomide in refractory multiple myeloma The New England Journal of Medicine 1999 341 21 1565 1571
135. Bartlett J. B., Dredge K., Dalgleish A. G., The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Reviews Cancer 2004 4 4 314 322 (Pubitemid 38525287)
136. Richardson P. G., Schlossman R. L., Weller E., Hideshima T., Mitsiades C., Davies F., Leblanc R., Catley L. P., Doss D., Kelly K., McKenney M., Mechlowicz J., Freeman A., Deocampo R., Rich R., Ryoo J. J., Chauhan D., Balinski K., Zeldis J., Anderson K. C., Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 2002 100 9 3063 3067 (Pubitemid 35217050)
137. D'Amato R. J., Lentzsch S., Anderson K. C., Rogers M. S., Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma Seminars in Oncology 2001 28 6 597 601 (Pubitemid 33134418)
138. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F. E., Tai Y. T., Treon S. P., Lin B., Schlossman R. L., Richardson P., Muller G., Stirling D. I., Anderson K. C., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 2000 96 9 2943 2950
139. Genentech, Avastin (bevacizumab) product insert 2011. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
140. Folprecht G., Khne C. H., The role of new agents in the treatment of colorectal cancer Oncology 2004 66 1 1 17 (Pubitemid 38410674)
141. Presta L. G., Chen H., O'Connor S. J., Chisholm V., Meng Y. G., Krummen L., Winkler M., Ferrara N., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Research 1997 57 20 4593 4599 (Pubitemid 27441066)
142. Salgaller M. L., Technology evaluation: bevacizumab, Genentech/Roche Current Opinion in Molecular Therapeutics 2003 5 6 657 667 (Pubitemid 38094437)
143. De Gramont V. C. E., Tabernero J., AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer 29, abstract no 362 Proceedings of the Gastrointestinal Cancer Symposium (ASCO) 2011
144. Allegra C. J., Yothers G., O'Connell M. J., Sharif S., Colangelo L. H., Lopa S. H., Petrelli N. J., Goldberg R. M., Atkins J. N., Seay T. E., Fehrenbacher L., O'Reilly S., Chu L., Azar C. A., Wolmark N., Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer Journal of Clinical Oncology 2009 27 20 3385 3390
145. Poultsides G. A., Servais E. L., Saltz L. B., Patil S., Kemeny N. E., Guillem J. G., Weiser M., Temple L. K. F., Wong W. D., Paty P. B., Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment Journal of Clinical Oncology 2009 27 20 3379 3384
146. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery 2004 3 5 391 400 (Pubitemid 38618122)
147. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J. O., Bodrogi I., Jagiello-Gruszfeld A., Moore N., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial The Lancet 2007 370 9605 2103 2111 (Pubitemid 350296300)
148. Rini B. I., Halabi S., Rosenberg J. E., Stadler W. M., Vaena D. A., Ou S.
149. Escudier B., Bellmunt J., Négrier S., Bajetta E., Melichar B., Bracarda S., Ravaud A., Golding S., Jethwa S., Sneller V., Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival Journal of Clinical Oncology 2010 28 13 2144 2150
150. Rini B. I., Halabi S., Rosenberg J. E., Stadler W. M., Vaena D. A., Archer L., Atkins J. N., Picus J., Czaykowski P., Dutcher J., Small E. J., Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 Journal of Clinical Oncology 2010 28 13 2137 2143
151. Gray R., Bhattacharya S., Bowden C., Miller K., Comis R. L., Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer Journal of Clinical Oncology 2009 27 30 4966 4972
152. Fojo T., Wilkerson J., Bevacizumab and breast cancer: the E2100 outlier The Lancet Oncology 2010 11 12 1117 1119
153. Klencke B., Bhattacharya S., Samant M. K., Independet review of E2100 progression-free survival (PFS) with the addition of bevacizumab (B) to paclitaxel (P) as initial chemotherpary for metastatic brease cancer (MBC) 26, abstract 1036 Proceedings of the 2008 ASCO Annual Meeting. Poster Discussion Session, Breast CancerMetastatic, 2008
154. Miles D. W., Chan A., Dirix L. Y., Cortés J., Pivot X., Tomczak P., Delozier T., Sohn J. H., Provencher L., Puglisi F., Harbeck N., Steger G. G., Schneeweiss A., Wardley A. M., Chlistalla A., Romieu G., Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer Journal of Clinical Oncology 2010 28 20 3239 3247
155. Robert N. J., Diéras V., Glaspy J., RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer Journal of Clinical Oncology 2011 29 10 1252 1260
156. Burstein H. J., Bevacizumab for advanced breast cancer: all tied up with a RIBBON? Journal of Clinical Oncology 2011 29 10 1232 1235
157. Hayes D. F., Bevacizumab treatment for solid tumors: boon or bust? Journal of the American Medical Association 2011 305 5 506 508
158. Ranpura V., Hapan S., Wu S., Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis Journal of the American Medical Association 2011 305 5 487 494
159. Herbst R. S., Hong W. K., IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer Seminars in Oncology 2002 29 5, supplement 14 18 30 (Pubitemid 35191043)
160. Herbst R. S., Kim E. S., Harari P. M., IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer Expert Opinion on Biological Therapy 2001 1 4 719 732 (Pubitemid 33769082)
161. Kim E. S., Khuri F. R., Herbst R. S., Epidermal growth factor receptor biology (IMC-C225) Current Opinion in Oncology 2001 13 6 506 513 (Pubitemid 33027904)
162. Sclabas G. M., Fujioka S., Schmidt C., Fan Z., Evans D. B., Chiao P. J., Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225 Journal of Gastrointestinal Surgery 2003 7 1 37 43 (Pubitemid 36875799)
163. Wainberg Z., Hecht J. R., Panitumumab in colon cancer: a review and summary of ongoing trials Expert Opinion on Biological Therapy 2006 6 11 1229 1235 (Pubitemid 44714148)
164. Saif M. W., Cohenuram M., Role of panitumumab in the management of metastatic colorectal cancer of metastatic colorectal cancer Clinical Colorectal Cancer 2006 6 2 118 124 (Pubitemid 44445746)
165. Gibson T. B., Ranganathan A., Grothey A., Randomized phase III trial results of Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer Clinical Colorectal Cancer 2006 6 1 29 31 (Pubitemid 44043998)
166. Tyagi P., Chu E., Jain V. K., Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer Clinical Colorectal Cancer 2005 5 1 21 23
167. Holash J., Davis S., Papadopoulos N., Croll S. D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J. P., Daly T., Wiegand S. J., Yancopoulos G. D., Rudge J. S., VEGF-Trap: a VEGF blocker with potent antitumor effects Proceedings of the National Academy of Sciences of the United States of America 2002 99 17 11393 11398 (Pubitemid 34920936)
168. Chu Q. S. C., Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors Expert Opinion on Biological Therapy 2009 9 2 263 271
169. Kim E. S., Serur A., Huang J., Manley C. A., McCrudden K. W., Frischer J. S., Soffer S. Z., Ring L., New T., Zabski S., Rudge J. S., Holash J., Yancopoulos G. D., Kandel J. J., Yamashiro D. J., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proceedings of the National Academy of Sciences of the United States of America 2002 99 17 11399 11404 (Pubitemid 34920937)
170. Jayson G. C., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., Broughton L., Wagstaff J., Hakannson L., Groenewegen G., Bailey J., Smith N., Hastings D., Lawrance J., Haroon H., Ward T., McGown A. T., Tang M., Levitt D., Marreaud S., Lehmann F. F., Herold M., Zwierzina H., Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies Journal of the National Cancer Institute 2002 94 19 1484 1493 (Pubitemid 35251753)
171. Jayson G. C., Mulatero C., Ranson M., Zweit J., Jackson A., Broughton L., Wagstaff J., Hakansson L., Groenewegen G., Lawrance J., Tang M., Wauk L., Levitt D., Marreaud S., Lehmann F. F., Herold M., Zwierzina H., Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer European Journal of Cancer 2005 41 4 555 563 (Pubitemid 40292735)
172. Wu Y., Zhong Z., Huber J., Bassi R., Finnerty B., Corcoran E., Li H., Navarro E., Balderes P., Jimenez X., Koo H., Mangalampalli V. R. M., Ludwig D. L., Tonra J. R., Hicklin D. J., Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer Clinical Cancer Research 2006 12 21 6573 6584 (Pubitemid 44799733)
173. Krupitskaya Y., Wakelee H. A., Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer Current Opinion in Investigational Drugs 2009 10 6 597 605
174. MacKey J., Gelmon K., Martin M., McCarthy N., Pinter T., Rupin M., Youssoufian H., TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer Clinical Breast Cancer 2009 9 4 258 261
175. Hudis C. A., Trastuzumabmechanism of action and use in clinical practice The New England Journal of Medicine 2007 357 1 39 51 (Pubitemid 47026733)
176. Casanovas O., Hicklin D. J., Bergers G., Hanahan D., Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 2005 8 4 299 309 (Pubitemid 41443415)
177. Ivy S. P., Wick J. Y., Kaufman B. M., An overview of small-molecule inhibitors of VEGFR signaling Nature Reviews Clinical Oncology 2009 6 10 569 579
178. Imai K., Takaoka A., Comparing antibody and small-molecule therapies for cancer Nature Reviews Cancer 2006 6 9 714 727 (Pubitemid 44286003)
179. Lowinger T. B., Riedl B., Dumas J., Smith R. A., Design and discovery of small molecules targeting raf-1 kinase Current Pharmaceutical Design 2002 8 25 2269 2278 (Pubitemid 35189900)
180. Richly H., Kupsch P., Passage K., Grubert M., Hilger R. A., Kredtke S., Voliotis D., Scheulen M. E., Seeber S., Strumberg D., A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors International Journal of Clinical Pharmacology and Therapeutics 2003 41 12 620 621
181. Faivre S., Demetri G., Sargent W., Raymond E., Molecular basis for sunitinib efficacy and future clinical development Nature Reviews Drug Discovery 2007 6 9 734 745 (Pubitemid 47338181)
182. Mendel D. B., Douglas Laird A., Xin X., Louie S. G., Christensen J. G., Li G., Schreck R. E., Abrams T. J., Ngai T. J., Lee L. B., Murray L. J., Carver J., Chan E., Moss K. G., Haznedar J.., Sukbuntherng J., Blake R. A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J. M., In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clinical Cancer Research 2003 9 1 I 327 337 (Pubitemid 36109749)
183. Schueneman A. J., Himmelfarb E., Geng L., Tan J., Donnelly E., Mendel D., McMahon G., Hallahan D. E., SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models Cancer Research 2003 63 14 4009 4016 (Pubitemid 36917920)
184. O'Farrell A. M., Abrams T. J., Yuen H. A., Ngai T. J., Louie S. G., Yee K. W. H., Wong L. M., Hong W., Lee L. B., Town A., Smolich B. D., Manning W. C., Murray L. J., Heinrich M. C., Cherrington J. M., SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 2003 101 9 3597 3605 (Pubitemid 36857948)
185. Motzer R. J., Hutson T. E., Tomczak P., Michaelson D., Bukowski R. M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., Chen I., Bycott P. W., Baum C. M., Figlin R. A., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma The New England Journal of Medicine 2007 356 2 115 124 (Pubitemid 46089672)
186. Motzer R. J., Agarwal N., Beard C., NCCN clinical practice guidelines in oncology: kidney cancer Journal of the National Comprehensive Cancer Network 2009 7 6 618 630
187. George S., Merriam P., Maki R. G., Van Den Abbeele A. D., Yap J. T., Akhurst T., Harmon D. C., Bhuchar G., O'Mara M. M., D'Adamo D. R., Morgan J., Schwartz G. K., Wagner A. J., Butrynski J. E., Demetri G. D., Keohan M. L., Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas Journal of Clinical Oncology 2009 27 19 3154 3160
188. Abraham R. T., Gibbons J. J., The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy Clinical Cancer Research 2007 13 11 3109 3114 (Pubitemid 46944891)
189. Sabatini D. M., mTOR and cancer: insights into a complex relationship Nature Reviews Cancer 2006 6 9 729 734 (Pubitemid 44286004)
190. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G. H., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R. J., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma The New England Journal of Medicine 2007 356 22 2271 2281 (Pubitemid 46849157)
191. Motzer R. J., Escudier B., Oudard S., Hutson T. E., Porta C., Bracarda S., Grnwald V., Thompson J. A., Figlin R. A., Hollaender N., Urbanowitz G., Berg W. J., Kay A., Lebwohl D., Ravaud A., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial The Lancet 2008 372 9637 449 456
192. Agarwala S. S., Case S., Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review Oncologist 2010 15 3 236 245
193. Sternberg C. N., Davis I. D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C. H., Salman P., Gladkov O. A., Kavina A., Zarb J. J., Chen M., McCann L., Pandite L., Roychowdhury D. F., Hawkins R. E., Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial Journal of Clinical Oncology 2010 28 6 1061 1068
194. Podar K., Tonon G., Sattler M., Tai Y. T., LeGouill S., Yasui H., Ishitsuka K., Kumar S., Kumar R., Pandite L. N., Hideshima T., Chauhan D., Anderson K. C., The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma Proceedings of the National Academy of Sciences of the United States of America 2006 103 51 19478 19483 (Pubitemid 46026056)
195. Rugo H. S., Herbst R. S., Liu G., Park J. W., Kies M. S., Steinfeldt H. M., Pithavala Y. K., Reich S. D., Freddo J. L., Wilding G., Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results Journal of Clinical Oncology 2005 23 24 5474 5483
196. Rini B. I., Wilding G., Hudes G., Stadler W. M., Kim S., Tarazi J., Rosbrook B., Trask P. C., Wood L., Dutcher J. P., Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma Journal of Clinical Oncology 2009 27 27 4462 4468
197. Schiller J. H., Larson T., Ou S. H. I., Limentani S., Sandler A., Vokes E., Kim S., Liau K., Bycott P., Olszanski A. J., Von Pawel J., Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study Journal of Clinical Oncology 2009 27 23 3836 3841
198. Spano J. P., Chodkiewicz C., Maurel J., Wong R., Wasan H., Barone C., Létourneau R., Bajetta E., Pithavala Y., Bycott P., Trask P., Liau K., Ricart A. D., Kim S., Rixe O., Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study The Lancet 2008 371 9630 2101 2108
199. Bendell J. C., Tournigand C., Bednarczyk T.C., Axitinib or bevacizumab plus FOLFOX or FOLFIRI as second-line therapy in patients with colorectal cancer 29, abstract 478 Proceedings of the Gastrointestinal Cancer Symposium (ASCO) 2011
200. Ito Y., Tokudome N., Sugihara T., Takahashi S., Hatake K., Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? Breast Cancer 2007 14 2 156 162
201. Moy B., Goss P. E., Lapatinib: current status and future directions in breast cancer Oncologist 2006 11 10 1047 1057 (Pubitemid 44788395)
202. Burris H. A., Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib Oncologist 2004 supplement 3 3 10 15
203. Montemurro F., Valabrega G., Aglietta M., Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity Expert Opinion on Biological Therapy 2007 7 2 257 268 (Pubitemid 46192173)
204. Geyer C. E., Forster J., Lindquist D., Chan S., Romieu C. G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S. D., Stein S., Cameron D., Lapatinib plus capecitabine for HER2-positive advanced breast cancer The New England Journal of Medicine 2006 355 26 2733 2743 (Pubitemid 46021510)
205. Konecny G. E., Pegram M. D., Venkatesan N., Finn R., Yang G., Rahmeh M., Untch M., Rusnak D. W., Spehar G., Mullin R. J., Keith B. R., Gilmer T. M., Berger M., Podratz K. C., Slamon D. J., Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Research 2006 66 3 1630 1639 (Pubitemid 43259947)
206. Chu I., Blackwell K., Chen S., Slingerland J., The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Research 2005 65 1 18 25 (Pubitemid 40070791)
207. Kerbel R. S., Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006 312 5777 1171 1175 (Pubitemid 43801134)
208. Kerbel R. S., Kamen B. A., The anti-angiogenic basis of metronomic chemotherapy Nature Reviews Cancer 2004 4 6 423 436 (Pubitemid 38745528)